Fusion IP, which commercialises university research, has signed an agreement with a pharmaceutical company utilising intellectual property out of the University of Sheffield, for the development of a known drug.
The agreement, which is worth over $500m per year is royalty-based, with limited milestone payments, will cover most of Fusion's net annual overheads.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The drug is currently at the second stage of development and is expected to make its first sales in 2015/16, with royalties to Fusion expected to peak at £1m per year.
Dr Andrew Tingey, Head of Licensing at Fusion, said: "This is an excellent licence for Fusion and demonstrates the value that can be unlocked through licensing the non spin-out opportunities within the Fusion pipeline."
The share price rose 10.39% to 42.5p by 12:40.
NR
-
How to boost your pension pot as 35% of UK over 50s face huge retirement savings gapOver 50s are facing a later life with little to no funds - but there are steps you can take now to boost your pot.
-
Zoopla: House sales fall for first time in two years as buyers wait for Autumn BudgetThe average price of a house in September was £270,000, down £1,000 from August as the housing market’s Christmas slowdown came early, Zoopla says
